Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Combo Products Exempt From Medicaid Rule Applying Price Inflation Rebates To Line Extensions

Executive Summary

CMS final rule narrows definition of new formulations potentially subject to much higher Medicaid rebates and delays effective date of provisions targeting health plan copay accumulator programs.

You may also be interested in...



Copay Assistance Can Be Excluded From Medicaid ‘Best Price’ Without Strings Attached – US Court

Decision is a win for the Pharmaceutical Research and Manufacturers of America in lawsuit against the US Health and Human Services Department.

Copay Assistance Programs Threatened By Medicaid Best Price Rule – PhRMA Lawsuit

The regulatory provisions being challenged are part of a Trump-era “midnight rule” that could be changed by the Biden Administration before implementation, but PhRMA is not taking any chances about the future of copay assistance programs.

CMS’ Brooks-LaSure: Early Action Impacting Pharma Likely To Focus On Legacy Trump Policies

Chiquita Brooks-LaSure’s nomination was approved in a 55-44 vote, with five Republicans joining Democrats in favor. Her confirmation clears the way for other appointments to key positions at the agency, such as the directors of the centers for Medicare and Medicaid.  

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS143538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel